Arjan A van de Loosdrecht

Summary

Affiliation: VU University Medical Center
Country: The Netherlands

Publications

  1. ncbi Emerging immunobiological concepts in macrophage and dendritic cell research and clinical implications
    Arjan A van de Loosdrecht
    Department of Hematology, VU-Institute of Cancer and Immunology (V-ICI, VU University Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, Netherlands
    Immunobiology 211:403-6. 2006
  2. ncbi Emerging antibody-targeted therapy in leukemia and lymphoma: current concepts and clinical implications
    Arjan A van de Loosdrecht
    Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands
    Anticancer Drugs 15:189-201. 2004
  3. ncbi Antibody-targeted therapy: a paradigm of innovative treatment strategies in indolent and aggressive B-cell non-Hodgkin lymphoma
    Arjan A van de Loosdrecht
    Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands
    Curr Opin Hematol 11:419-25. 2004
  4. ncbi The dendritic cell: the piano player in orchestrating the immune response in leukemia
    Arjan A van de Loosdrecht
    Department of Hematology, VU Institute for Cancer and Immunology, VU University Medical Center, Amsterdam, The Netherlands
    Leuk Lymphoma 48:217-8. 2007
  5. ncbi Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes
    Arjan A van de Loosdrecht
    Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands
    Haematologica 94:1124-34. 2009
  6. ncbi Identification of distinct prognostic subgroups in low- and intermediate-1-risk myelodysplastic syndromes by flow cytometry
    Arjan A van de Loosdrecht
    Department of Hematology, Vrije Universiteit VU University Medical Center, VU Institute for Cancer and Immunology, Amsterdam, The Netherlands
    Blood 111:1067-77. 2008
  7. ncbi Serum-free generation of antigen presenting cells from acute myeloid leukaemic blasts for active specific immunisation
    Ilse Houtenbos
    Department of Haematology BR 250, VU University Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands
    Cancer Immunol Immunother 52:455-62. 2003
  8. ncbi Targeting Toll-like receptor 7/8 enhances uptake of apoptotic leukemic cells by monocyte-derived dendritic cells but interferes with subsequent cytokine-induced maturation
    Willemijn van den Ancker
    Department of Hematology, Cancer Center Amsterdam, VU Institute for Cancer and Immunology, VU University Medical Center, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands
    Cancer Immunol Immunother 60:37-47. 2011
  9. ncbi The novel bispecific diabody alphaCD40/alphaCD28 strengthens leukaemic dendritic cell-induced T-cell reactivity
    Ilse Houtenbos
    Department of Haematology, VU University Medical Centre, Amsterdam, The Netherlands
    Br J Haematol 142:273-83. 2008
  10. ncbi Impaired antigen presentation in neoplasia: basic mechanisms and implications for acute myeloid leukemia
    Marvin M van Luijn
    Department of Hematology, VU Institute for Cancer and Immunology, Cancer Center Amsterdam, VU University Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands
    Immunotherapy 2:85-97. 2010

Detail Information

Publications44

  1. ncbi Emerging immunobiological concepts in macrophage and dendritic cell research and clinical implications
    Arjan A van de Loosdrecht
    Department of Hematology, VU-Institute of Cancer and Immunology (V-ICI, VU University Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, Netherlands
    Immunobiology 211:403-6. 2006
  2. ncbi Emerging antibody-targeted therapy in leukemia and lymphoma: current concepts and clinical implications
    Arjan A van de Loosdrecht
    Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands
    Anticancer Drugs 15:189-201. 2004
    ..An update is provided on the use of Ab-targeted therapies in clinical trials with emphasis on new emerging strategies to further expand the successful field of immunotherapy in leukemia and lymphoma...
  3. ncbi Antibody-targeted therapy: a paradigm of innovative treatment strategies in indolent and aggressive B-cell non-Hodgkin lymphoma
    Arjan A van de Loosdrecht
    Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands
    Curr Opin Hematol 11:419-25. 2004
    ....
  4. ncbi The dendritic cell: the piano player in orchestrating the immune response in leukemia
    Arjan A van de Loosdrecht
    Department of Hematology, VU Institute for Cancer and Immunology, VU University Medical Center, Amsterdam, The Netherlands
    Leuk Lymphoma 48:217-8. 2007
  5. ncbi Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes
    Arjan A van de Loosdrecht
    Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands
    Haematologica 94:1124-34. 2009
    ..Standardization of FCM in myelodysplastic syndromes may thus contribute to improved diagnosis and prognostication of myelodysplastic syndromes in the future...
  6. ncbi Identification of distinct prognostic subgroups in low- and intermediate-1-risk myelodysplastic syndromes by flow cytometry
    Arjan A van de Loosdrecht
    Department of Hematology, Vrije Universiteit VU University Medical Center, VU Institute for Cancer and Immunology, Amsterdam, The Netherlands
    Blood 111:1067-77. 2008
    ....
  7. ncbi Serum-free generation of antigen presenting cells from acute myeloid leukaemic blasts for active specific immunisation
    Ilse Houtenbos
    Department of Haematology BR 250, VU University Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands
    Cancer Immunol Immunother 52:455-62. 2003
    ..These AML-APCs are suitable for the development of active specific immunisation protocols which meet the criteria for good clinical practise (GCP)...
  8. ncbi Targeting Toll-like receptor 7/8 enhances uptake of apoptotic leukemic cells by monocyte-derived dendritic cells but interferes with subsequent cytokine-induced maturation
    Willemijn van den Ancker
    Department of Hematology, Cancer Center Amsterdam, VU Institute for Cancer and Immunology, VU University Medical Center, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands
    Cancer Immunol Immunother 60:37-47. 2011
    ..Taken together, our data demonstrate that even though R848 improved uptake of apoptotic leukemic cells, the sequential use of R848 and CC is counter-indicated due to its adverse effects on MoDC maturation...
  9. ncbi The novel bispecific diabody alphaCD40/alphaCD28 strengthens leukaemic dendritic cell-induced T-cell reactivity
    Ilse Houtenbos
    Department of Haematology, VU University Medical Centre, Amsterdam, The Netherlands
    Br J Haematol 142:273-83. 2008
    ..We propose that the alphaCD40/alphaCD28-bispecific diabody can serve as a potent therapeutic tool to effectively augment anti-tumour T-cell responses elicited by AML-DC...
  10. ncbi Impaired antigen presentation in neoplasia: basic mechanisms and implications for acute myeloid leukemia
    Marvin M van Luijn
    Department of Hematology, VU Institute for Cancer and Immunology, Cancer Center Amsterdam, VU University Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands
    Immunotherapy 2:85-97. 2010
    ....
  11. ncbi Alternative Ii-independent antigen-processing pathway in leukemic blasts involves TAP-dependent peptide loading of HLA class II complexes
    Marvin M van Luijn
    Department of Hematology, Cancer Center Amsterdam, VU Institute for Cancer and Immunology, VU University Medical Center, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands
    Cancer Immunol Immunother 59:1825-38. 2010
    ....
  12. ncbi Chronic myeloid leukemia lysate-loaded dendritic cells induce T-cell responses towards leukemia progenitor cells
    Theresia M Westers
    Department of Hematology, Cancer Center Amsterdam VUmc Institute for Cancer and Immunology, VU University Medical Center, Amsterdam, The Netherlands
    Immunotherapy 3:569-76. 2011
    ..Our data show the potency of dendritic cell-based vaccination strategies for the induction of T cell-mediated responses to eradicate minimal residual disease...
  13. ncbi Absence of class II-associated invariant chain peptide on leukemic blasts of patients promotes activation of autologous leukemia-reactive CD4+ T cells
    Marvin M van Luijn
    Department of Hematology, Cancer Center Amsterdam and VU Institute for Cancer and Immunology, VU University Medical Center, The Netherlands
    Cancer Res 71:2507-17. 2011
    ..Our findings offer a clinical rationale to downmodulate CLIP on leukemic blasts as a strategy to degrade immune escape and improve leukemia-specific T-cell immunity in AML patients...
  14. ncbi Class II-associated invariant chain peptide down-modulation enhances the immunogenicity of myeloid leukemic blasts resulting in increased CD4+ T-cell responses
    Marvin M van Luijn
    Department of Hematology, VU Institute for Cancer and Immunology, Cancer Center Amsterdam, VU University Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands
    Haematologica 95:485-93. 2010
    ..The current study investigates the role of aberrant HLA class II antigen presentation on leukemic blasts by determining both the clinical and functional impact of the class II-associated invariant chain peptide (CLIP)...
  15. ncbi Azacitidine differentially affects CD4(pos) T-cell polarization in vitro and in vivo in high risk myelodysplastic syndromes
    Hetty J Bontkes
    Department of Hematology, VU University Medical Center, Cancer Center Amsterdam, De Boelelaan 1117, 1081HV Amsterdam, The Netherlands
    Leuk Res 36:921-30. 2012
    ..03) and in vivo (p < 0.006), indicating that Aza directly affects CD4(pos) polarization during activation in vitro. Upon in vivo treatment in high risk MDS patients, particularly the T(H)17-Treg axis is affected...
  16. ncbi Feasibility of clinical dendritic cell vaccination in acute myeloid leukemia
    Ilse Houtenbos
    Department of Hematology, VU University Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands
    Immunobiology 211:677-85. 2006
    ..Clinical relevant responses to DC-based immunotherapy are likely to only occur in non-end-stage patients. Application in early stage disease is mandatory to permit ultimate proof of clinical benefit of AML-DC vaccination strategy...
  17. ncbi Leukemia-specific T-cell reactivity induced by leukemic dendritic cells is augmented by 4-1BB targeting
    Ilse Houtenbos
    Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands
    Clin Cancer Res 13:307-15. 2007
    ..Engagement of the costimulatory molecule 4-1BB can break immunologic tolerance and increase CTL responses. In this study, we examined the role of the 4-1BB ligand (4-1BBL) on T-cell responses induced by AML-DC...
  18. ncbi Recent advances in antigen-loaded dendritic cell-based strategies for treatment of minimal residual disease in acute myeloid leukemia
    Willemijn van den Ancker
    Department of Hematology, VU Institute for Cancer and Immunology, Cancer Center Amsterdam, VU University Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands
    Immunotherapy 2:69-83. 2010
    ..This review discusses recent advances in DC research and the application of this knowledge towards new strategies for antigen loading of DCs in the treatment of minimal residual disease in acute myeloid leukemia...
  19. ncbi Aberrant immunophenotype of blasts in myelodysplastic syndromes is a clinically relevant biomarker in predicting response to growth factor treatment
    Theresia M Westers
    Department of Hematology, Vrije Universiteit VU University Medical Center, Amsterdam, The Netherlands
    Blood 115:1779-84. 2010
    ..In conclusion, FCM may add significantly to well-known predictive parameters in selecting MDS patients eligible for Epo/G-CSF treatment. This is of relevance regarding prevention of treatment failure...
  20. ncbi Quantification of T-cell-mediated apoptosis in heterogeneous leukemia populations using four-color multiparameter flow cytometry
    Theresia M Westers
    Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands
    Cytometry A 66:71-7. 2005
    ..1% and 8.4% for cell lines and leukemic samples, respectively. CONCLUSION: The presented flow cytometric cytotoxicity assay enables the study of T-cell-mediated apoptosis in a heterogenous leukemia population...
  21. ncbi Promiscuous binding of invariant chain-derived CLIP peptide to distinct HLA-I molecules revealed in leukemic cells
    Marvin M van Luijn
    Department of Hematology, VU Institute for Cancer and Immunology, VU University Medical Center, Amsterdam, The Netherlands
    PLoS ONE 7:e34649. 2012
    ..The found participation of CLIP in the HLA-I antigen presentation pathway could reflect an aberrant mechanism in leukemic cells, but might also lead to elucidation of novel processing pathways or immune escape mechanisms...
  22. ncbi Class II-associated invariant chain peptide expression represents a novel parameter for flow cytometric detection of acute promyelocytic leukemia
    Marvin M van Luijn
    Department of Hematology, Cancer Center Amsterdam, VU Institute for Cancer and Immunology, VU University Medical Center, Amsterdam, The Netherlands
    Am J Pathol 179:2157-61. 2011
    ..Our findings show the additive value of CLIP analysis for a fast and unequivocal recognition of APL by flow cytometry in conjunction with morphology...
  23. ncbi Detection of aberrant transcription of major histocompatibility complex class II antigen presentation genes in chronic lymphocytic leukaemia identifies HLA-DOA mRNA as a prognostic factor for survival
    Yuri Souwer
    Department of Immunopathology, Sanquin Research and Landsteiner Laboratory, Academical Medical Centre, University of Amsterdam, Amsterdam, The Netherlands
    Br J Haematol 145:334-43. 2009
    ..Multivariate analysis revealed that the prognostic value of DOA mRNA was independent of the mutational status of the IGHV genes. Thus, aberrant transcription of DOA forms a novel and additional prognostic indicator for survival in B-CLL...
  24. ncbi Role of immune responses in the pathogenesis of low-risk MDS and high-risk MDS: implications for immunotherapy
    Shikhar Aggarwal
    Department of Haematology, VU Institute for Cancer and Immunology, VU University Medical Centre, Amsterdam, The Netherlands
    Br J Haematol 153:568-81. 2011
    ..This review is focused on the role of immune responses in MDS and the implications for the development of novel immune therapies...
  25. ncbi Immune mediated autologous cytotoxicity against hematopoietic precursor cells in patients with myelodysplastic syndrome
    Martine E D Chamuleau
    Department of Hematology, VU University Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands
    Haematologica 94:496-506. 2009
    ..Immune activation could reflect undesired autoimmune reactions against normal hematopoietic precursor cells as well as effective immune-surveillance against dysplastic clones...
  26. ncbi Dendritic cell-based immunotherapy in acute and chronic myeloid leukaemia
    Theresia M Westers
    Department of Haematology, VU University Medical Centre, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands
    Biomed Pharmacother 61:306-14. 2007
    ..This review summarises data on active specific DC-based immunotherapy in acute and chronic myeloid leukaemia and discusses current optimisation strategies...
  27. ncbi Review of the relevance of aberrant antigen expression by flow cytometry in myeloid neoplasms
    Gert J Ossenkoppele
    Department of Haematology, VU University Medical Center, De Boelelaan 1117, Amsterdam, The Netherlands
    Br J Haematol 153:421-36. 2011
    ....
  28. ncbi Monoclonal antibody therapy in haematological malignancies
    Martine E D Chamuleau
    Department of Haematology, VU University Medical Center, 1081 HV Amsterdam, The Netherlands
    Curr Clin Pharmacol 5:148-59. 2010
    ..Therefore, also some interesting phase III studies that are recruiting patients at this moment, and some new technical developments are discussed...
  29. ncbi Employing the immunological synapse in AML: development of leukemic dendritic cells for active specific immunization
    Ilse Houtenbos
    Department of Hematology, VU University Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands
    Immunobiology 210:249-57. 2005
    ..This review discusses increased immunogenicity of AML blasts by differentiation into AML-DC and describes ways to augment the AML-DC vaccination approach...
  30. ncbi Class II-associated invariant chain peptide expression on myeloid leukemic blasts predicts poor clinical outcome
    Martine E D Chamuleau
    Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands
    Cancer Res 64:5546-50. 2004
    ..We hypothesize that DR+/CLIP- AML blasts are able to present leukemia-specific antigens to CD4+ T helper cells initiating an effective and long-lasting antitumor response resulting in a prolonged disease-free survival...
  31. ncbi Implementation of flow cytometry in the diagnostic work-up of myelodysplastic syndromes in a multicenter approach: report from the Dutch Working Party on Flow Cytometry in MDS
    Theresia M Westers
    Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands
    Leuk Res 36:422-30. 2012
    ..Over the years (2005-2011), the concordance between the participating centers increased indicating that the proposed guidelines contributed to a more objective, standardized FC analysis, thereby ratifying the implementation of FC in MDS...
  32. ncbi Principles of dendritic cell-based immunotherapy in myeloid leukemia
    Theresia M Westers
    Department of Hematology, VU University Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands
    Immunobiology 211:663-76. 2006
    ..This review discusses the function and the applicability of leukemia-derived DCs for active specific immunotherapy in myeloid leukemia including possible pitfalls, and describes options to optimize DC-based vaccines...
  33. ncbi Leukemia-derived dendritic cells: towards clinical vaccination protocols in acute myeloid leukemia
    Ilse Houtenbos
    Department of Hematology, VU University Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands
    Haematologica 91:348-55. 2006
    ..This review describes ways to improve AML-DC vaccines and discusses critical aspects concerning the development of clinical vaccination protocols...
  34. ncbi Human dendritic cell line models for DC differentiation and clinical DC vaccination studies
    Saskia J A M Santegoets
    Department of Pathology, VU University Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands
    J Leukoc Biol 84:1364-73. 2008
    ....
  35. ncbi High INDO (indoleamine 2,3-dioxygenase) mRNA level in blasts of acute myeloid leukemic patients predicts poor clinical outcome
    Martine E D Chamuleau
    Department of Hematology, VU University Medical Centre, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands
    Haematologica 93:1894-8. 2008
    ..Inhibition of indoleamine 2,3-dioxygenase expressed by myeloid leukemic blasts may result in breaking immune tolerance and offers new therapeutic options for patients with acute myeloid leukemia...
  36. ncbi Radioimmunotherapy for indolent B-cell non-Hodgkin lymphoma in relapsed, refractory and transformed disease
    Otto J Visser
    Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands
    BioDrugs 20:201-7. 2006
    ..The encouraging results of RIT in indolent NHL have initiated studies focusing on its benefit for patients with aggressive NHL...
  37. ncbi Rapid generation of antigen-presenting cells from leukaemic blasts in acute myeloid leukaemia
    Theresia M Westers
    Department of Haematology, VU University Medical Centre, De Boelelaan 1117, Amsterdam, 1081 HV, The Netherlands
    Cancer Immunol Immunother 52:17-27. 2003
    ....
  38. ncbi Efficacy of single-agent lenalidomide in patients with JAK2 (V617F) mutated refractory anemia with ring sideroblasts and thrombocytosis
    Gerwin Huls
    Department of Hematology, University Medical Center Groningen, University of Groningen, Hanzeplein 1, Groningen, The Netherlands
    Blood 116:180-2. 2010
    ..Both patients became transfusion independent, and 1 of the patients attained indeed a complete molecular remission...
  39. ncbi Sequential organ failure predicts mortality of patients with a haematological malignancy needing intensive care
    Alexander D Cornet
    Department of Intensive Care, Institute for Cardiovascular Research, Vrije Universiteit Medical Centre, Amsterdam, The Netherlands
    Eur J Haematol 74:511-6. 2005
    ..The latter may help us to decide on intensive care in individual cases, in order to avoid potentially futile care for patients with a SOFA score of 15 or higher...
  40. ncbi Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial
    Helga J Droogendijk
    Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
    Cancer 107:345-51. 2006
    ..In general, imatinib mesylate was tolerated well. CONCLUSIONS: Imatinib mesylate was effective in patients with systemic mastocytosis, including those who had the D816V mutation...
  41. ncbi Flowcytometry in myelodysplastic syndromes: towards a new paradigm in diagnosis and prognostication?
    Arjan A van de Loosdrecht
    Leuk Res 32:205-7. 2008
  42. ncbi Superior activity of fusion protein scFvRit:sFasL over cotreatment with rituximab and Fas agonists
    Edwin Bremer
    Groningen University Institute for Drug Exploration, Department of Pathology and Laboratory Medicine, University Medical Center Groningen, Groningen, The Netherlands
    Cancer Res 68:597-604. 2008
    ..In conclusion, scFvRit:sFasL efficiently activates CD20 and Fas-apoptotic signaling and may be useful for the elimination of malignant B cells...
  43. ncbi Divergent autologous T cell responses to leukaemic dendritic cells during remission in acute promyelocytic leukaemia
    Theresia M Westers
    Cell Oncol 27:261-6. 2005
  44. ncbi Back to basics: in search of the optimal dendritic cell for vaccination in AML
    Willemijn van den Ancker
    Leuk Res 32:1641-3. 2008